August 10, 2020 – Thermo Fisher Scientific (Waltham, MA) has developed a new serological assay targeted towards transplant candidates and recipients that can detect antibodies directed against COVID-19 (SARS-CoV-2). The assay will be provided under the company’s One Lambda brand.
In collaboration with histocompatibility, infectious disease and nephrology laboratories at Emory University, Stanford University, University of Cincinnati and the University Health Network in Toronto, Thermo Fisher’s transplant diagnostic business has developed the LABScreen COVID Plus Assay.
The assay leverages the Luminex xMAP technology to detect multiple distinct antibodies and fragments, making it more specific than current assays and able to reduce false positives caused by infections with common coronavirus. According to the company, in combination with HLA antibody detection, the LABScreen COVID Plus reagents can help provide a more complete picture of a patient’s antibody profile.
The LABScreen COVID Plus Assay will be available for research use only by August 2020, the company says. Additionally, the assay will be submitted for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.